针对STAT3的siRNA抑制HepG2细胞增殖和p44/42MAPK蛋白的表达*

doi:10.3969/j.issn.1672-5069.2010.06.001

实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (6): 401-403.doi: 10.3969/j.issn.1672-5069.2010.06.001

• 论著 • 下一篇

针对STAT3的siRNA抑制HepG2细胞增殖和p44/42MAPK蛋白的表达*

王新红,邢慧,陈晶,范玉晶,刘丹,刘红霞,吕志武

150086 哈尔滨市哈尔滨医科大学附属第二医院消化内科

收稿日期:2010-07-21 出版日期:2010-12-10 发布日期:2016-04-18
通讯作者: 吕志武，E-mail：drzwl@yahoo.com.cn
作者简介:王新红女，34岁，医学博士，主治医师。主要从事消化内科疾病的诊治及发病机制研究。E-mail：yuner1976@126.com
基金资助:
黑龙江省教育厅基金资助项目（编号：11531190）；哈尔滨医科大学附属第二医院青年基金资助项目（编号：QN2007-17）

Inhibition of cell growth and p44/42MAPK protein expression by siRNA against STAT3 in HepG2 cells in vitro

WANG Xinhong，XING Hui，CHEN Jing，et al.

Department of Gastroenterology，Second Hospital Affiliated to Harbin Medical University，Harbin 150086，Heilongjiang Province，China

Received:2010-07-21 Online:2010-12-10 Published:2016-04-18

摘要/Abstract

摘要： 目的研究STAT3信号传导通路对HepG2细胞p44/42MAPK蛋白表达和细胞生长的影响。方法将针对STAT3的siRNA转染入HepG2细胞以沉默STAT3基因的表达，采用MTT法检测细胞生长，采用Western blot法检测STAT3和p44/42MAPK蛋白的表达。结果对照组和lipofectamineTM2000处理组细胞生长无明显差异（q=0.97，P>0.05），而siRNA处理组细胞生长被明显抑制（q=9.36，P<0.05）；SiRNA转染后24h、48h、72h和96h，细胞抑制率分别为33.2%、39.6%、43.1%和33.9%，siRNA在96h后抑制作用减弱，细胞开始重新繁殖；转染细胞72h和96h后，可见STAT3蛋白表达均被抑制（t=14.12，P<0.05），p44/42MAPK蛋白表达未被抑制（F=3.99，P>0.05），而p-p44/42MAPK蛋白表达增加（t=16.30，P<0.05）。结论 STAT3信号传导通路可以影响细胞生长及p44/42MAPK蛋白质的磷酸化，而p-p44/42MAPK的表达增加可能代偿了沉默STAT3引起的细胞生长抑制，使细胞重新繁殖。

关键词: HepG2细胞, RNA干扰, 转录信号转导子与激活子3, P44/42丝裂素活化蛋白激酶, 信号传导通路

Abstract: Objective To study the effect of STAT3 signaling pathways on p44/42MAPK and cell growth in hepatocellular carcinoma. Methods The siRNA directed against STAT3 was transfected into HepG2 cells. Cell growth was measured by MTT assay and STAT3 and p44/42MAPK protein expression were measured by Western blot. Results A significant decrease in the number of viable cells（q=9.36，P<0.05）was found in the siRNA transfection group as compared to that in the control or the LipofectamineTM2000 transfected groups；SiRNA inhibited cell growth with the inhibition rates of 33.2% at 24h，39.6% at 48h，43.1% at 72h，and 33.9% at 96h；At 72h and 96h after the transfection，STAT3 protein expression was inhibited and P44/42MAPK protein expression was not influenced and p-p44/42MAPK protein expression was increased.Conclusion siRNA against STAT3 may affect cell growth in vitro.

Key words: HepG2 cell, RNA interference, Signal transducers and activators of transcription 3, p44/42MAPK, Signaling pathway

王新红,邢慧,陈晶,范玉晶,刘丹,刘红霞,吕志武. 针对STAT3的siRNA抑制HepG2细胞增殖和p44/42MAPK蛋白的表达*[J]. 实用肝脏病杂志, 2010, 13(6): 401-403.

WANG Xinhong，XING Hui，CHEN Jing，et al.. Inhibition of cell growth and p44/42MAPK protein expression by siRNA against STAT3 in HepG2 cells in vitro[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(6): 401-403.

参考文献

[1] YAO Z， MISHRA L. Cancer stem cells and hepatocellular carcinoma[J]. Cancer Biol Ther，2009，8:1691-1698.
[2] LEONG PL，ANDREWS GA，JOHNSON DE，et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth[J]. Proc Natl Acad Sci USA，2003，100:4138-4143.
[3] BESSARD A，FREMIN C，EZAN F，et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo[J]. Oncogene，2008，27（40）:5315-5325.
[4] SHAMA J，GARCIA-MEDINA R，POUYSSEGUR J，et al. Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells[J]. Biochem Biophys Res Commun，2008，372（4）:845-849.
[5] MARINO VJ，ROGUIN LP. The granulocyte colony stimulating factor（G-CSF）activates Jak/STAT and MAPK pathways in a trophoblastic cell line[J]. J Cell Biochem，2008，103（5）:1512-1523.
[6] XUAN YT，GUO Y，ZHU Y，et al. Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning[J]. Circulation，2005，112（13）:1971-1978.
[7] LIZA K，MACIEJ K，MATHEW MK，et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells[J]. BMC Cancer，2003，3:23-32.
[8] HE S，ZHANG D，CHENG F，et al. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression[J]. Mol Biol Rep，2009，36:2153-2163.
[9] BEHERA R，KUMAR V，LOHITE K，et al. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells[J]. Carcinogenesis，2010，31:192-200.
[10] YANG C，SCHWAB JH， SCHOENFELD AJ，et al. A novel target for treatment of chordoma:signal transducers and activators of transcription 3[J]. Mol Cancer Ther，2009，8:2597-2605.
[11] SHAMA J，GARCIA-MEDINA R，POUYSSEGUR J，et al. Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells[J]. Biochem Biophys Res Commun，2008，372:845-849.
[12] VELLON L，MENENDEZ JA，LUPU R. A bidirectional “alpha（v）beta（3）integrin-ERK1/ERK2 MAPK”connection regulates the proliferation of breast cancer cells[J]. Mol Carcinog，2006，45:795-804.
[13] FUJII H，ITOH Y，YAMAGUCHi K，et al. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro[J]. Biochem Biophys Res Commun，2004，322:1052-1058.

[1]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[2]	王爽, 许坚吉, 刘晓霓, 陈德喜. 荧光素酶生物发光报告体系的优化及在肝癌荷瘤裸鼠模型中的应用^*[J]. 实用肝脏病杂志, 2019, 22(4): 482-485.
[3]	曹白鸽,刘冲霄,陈源文,董艳. IL-6上调SCD1表达对HepG2细胞脂质合成功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 172-175.
[4]	张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.
[5]	姜哲, 舒敏, 王媛媛, 朴莲淑. miR-363靶向调控E2F3表达影响HepG2细胞增殖和凋亡研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 825-828.
[6]	欧志涛, 詹远京, 郭家伟, 罗铎. CIAPIN1对HepG2细胞增殖和细胞周期的影响[J]. 实用肝脏病杂志, 2018, 21(1): 38-41.
[7]	王以浪，印滇，杨莉，张亮，姚登福. 胰岛素抵抗肝癌细胞IGF-1R/NF-κB表达及多药耐药机制研究[J]. 实用肝脏病杂志, 2016, 19(6): 704-708.
[8]	丁宁, 张明香. 人HNF4α基因真核表达载体的构建与鉴定^*[J]. 实用肝脏病杂志, 2016, 19(2): 156-159.
[9]	郭灿, 曾莉. 疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性的保护作用[J]. 实用肝脏病杂志, 2016, 19(2): 160-163.
[10]	李平(综述), 汪茂荣(审校). 丙型肝炎病毒感染与2型糖尿病相关性研究进展[J]. 实用肝脏病杂志, 2016, 19(2): 253-256.
[11]	赵斐, 谢萍, 姜佳丽, 张令强, 安威, 展玉涛. 他莫昔芬体外促进HepG2细胞脂肪变性观察^*[J]. 实用肝脏病杂志, 2014, 17(1): 30-33.
[12]	梁慧敏, 时小燕, 和振坤, 徐庆杰. 黄芩苷诱导人肝癌HepG-2细胞凋亡作用观察[J]. 实用肝脏病杂志, 2012, 15(4): 343-345.
[13]	彭梅娟, 郝春秋, 张, 野, 谢玉梅, 张, 岩, 白雪帆. 慢病毒载体介导的结缔组织生长因子基因沉默对下游基因的影响^*[J]. 实用肝脏病杂志, 2012, 15(3): 212-215.
[14]	陈启斌, 荚卫东. RNA干扰及其在肝癌治疗中的研究进展*[J]. 实用肝脏病杂志, 2012, 15(1): 78-80.
[15]	邓豫,王桂华,金源,李小兰,陶德定,李维娜,龚建平,胡俊波. TAT-N24穿膜融合多肽对HepG2细胞增殖的影响^*[J]. 实用肝脏病杂志, 2011, 14(5): 321-322.

针对STAT3的siRNA抑制HepG2细胞增殖和p44/42MAPK蛋白的表达*

Inhibition of cell growth and p44/42MAPK protein expression by siRNA against STAT3 in HepG2 cells in vitro

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价